More about

Hepatocellular Carcinoma

News
November 08, 2022
2 min read
Save

‘Significant’ racial, ethnic disparities exist in curative treatment for early-stage HCC

‘Significant’ racial, ethnic disparities exist in curative treatment for early-stage HCC

WASHINGTON — Fewer Black and Hispanic patients received curative treatment for early-stage hepatocellular carcinoma compared with white patients, according to research presented at The Liver Meeting.

News
November 06, 2022
2 min read
Save

MMaT-3 policy decreases survival, increases recurrence after transplant in HCC patients

MMaT-3 policy decreases survival, increases recurrence after transplant in HCC patients

WASHINGTON — The MELD score at transplant minus three points policy led to poor survival and recurrence outcomes after liver transplantation among patients with hepatocellular carcinoma, according to research at The Liver Meeting.

News
November 02, 2022
1 min read
Save

FDA grants orphan drug designation to OTX-2002 for hepatocellular carcinoma

FDA grants orphan drug designation to OTX-2002 for hepatocellular carcinoma

The FDA granted orphan drug designation to OTX-2002 for the treatment of hepatocellular carcinoma, according to the agent’s manufacturer.

News
September 16, 2022
2 min read
Save

Risk for liver cancer rises with each generation among US residents of Mexican descent

Risk for liver cancer rises with each generation among US residents of Mexican descent

Second- and third-generation individuals of Mexican descent who reside in the U.S. had a higher risk for developing hepatocellular carcinoma than first-generation U.S. Mexicans, according to study results.

News
September 06, 2022
2 min read
Save

Exposure to widespread synthetic pollutants linked to surprising ‘magnitude’ of HCC risk

Exposure to widespread synthetic pollutants linked to surprising ‘magnitude’ of HCC risk

Investigators have identified an elevated risk for hepatocellular carcinoma in people exposed to per- and polyfluoroalkyl substances, according to a study published in JHEP Reports.

News
August 31, 2022
1 min read
Save

Liver transplantation ‘remains the standard of care’ for HCC patients, regardless of age

Liver transplantation ‘remains the standard of care’ for HCC patients, regardless of age

Despite increased perioperative risks in older patients with hepatocellular carcinoma and cirrhosis, orthotropic liver transplantation provides greater survival benefit compared with ablative therapies, according to new research.

News
August 29, 2022
3 min read
Save

Nomograms predict risk for early death in HCC, may guide ‘individualized treatment’

Nomograms predict risk for early death in HCC, may guide ‘individualized treatment’

Internally validated nomograms predicted the probability of early death and identified risk factors among patients with advanced hepatocellular carcinoma, according to research published in BMC Gastroenterology.

News
August 22, 2022
2 min read
Save

Downstaging HCC to Milan criteria prior to liver transplant yield ‘excellent outcomes’

Downstaging HCC to Milan criteria prior to liver transplant yield ‘excellent outcomes’

Researchers reported excellent 10-year outcomes among patients with hepatocellular carcinoma that was downstaged to within Milan criteria prior to liver transplant, according to a multicenter analysis published in JAMA Surgery.

News
August 19, 2022
1 min read
Save

Top in GI: Viruses implicated in hepatitis surge; NASH is driving liver cancer deaths

Top in GI: Viruses implicated in hepatitis surge; NASH is driving liver cancer deaths

A combination of viruses has been linked to an unexplained surge of severe hepatitis in children.

News
August 09, 2022
1 min read
Save

Phase 3 trial of tislelizumab in hepatocellular carcinoma meets survival endpoint

A phase 3 trial of the PD-1 inhibitor tislelizumab met its primary endpoint of noninferior OS compared with sorafenib as first-line treatment for adults with unresectable hepatocellular carcinoma, according to the agent’s manufacturer.

View more